Literature DB >> 9604120

Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats.

P J Sinko1, P V Balimane.   

Abstract

The mechanism of intestinal transport of valacyclovir (VACV), the L-valyl ester prodrug of acyclovir, was investigated in rats using an in situ intestinal perfusion technique. VACV demonstrates an oral bioavailability that is three to five time greater than acyclovir, concentration dependent, and saturable in humans. Homogenate and perfused buffer stability results demonstrated that VACV was increasingly unstable with increasing pH. VACV was converted to ACV in a concentration dependent manner during a single pass through the intestinal segment. Perfusions were performed at 37 degrees C, pH 6.5, and under iso-osmotic conditions (290 +/- 10 mOsm L-1). Intestinal outlet concentrations were corrected for VACV that was converted to ACV during the perfusion. The effective dimensionless intestinal permeability (P*e) of VACV was concentration dependent, saturable (intrinsic Km = 1.2 +/- 0.7 mM), and significantly reduced (p < 0.05) in the presence of peptide analogues (amoxicillin, ampicillin, cefadroxil, and cephradine), by the organic anion, p-amino hippuric acid and by the organic cation quinine. VACV transport was not inhibited by classical nucleoside competitive substrates or inhibitors or by valine. These results suggest that H(+)-oligopeptide, H(+)-organic cation, and organic anion transporters are involved in the small intestinal uptake of VACV. The permeability of VACV in the colon was very low, indicating that VACV is predominantly absorbed from the small intestine. VACV P*e was not altered in the presence of glucose-induced convective fluid flow, suggesting that carrier-mediated, transcellular uptake is the predominant absorption pathway of VACV in rat small intestine. Based on these results, the oral bioavailability of VACV appears to be significantly influenced by the preabsorptive conversion of VACV to the poorly absorbed ACV, by the involvement of multiple transporters in VACV small-intestinal uptake, and by the low permeability of VACV in the colon.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9604120     DOI: 10.1002/(sici)1099-081x(199805)19:4<209::aid-bdd93>3.0.co;2-o

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  21 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Targeted prodrug design to optimize drug delivery.

Authors:  H K Han; G L Amidon
Journal:  AAPS PharmSci       Date:  2000

3.  Glutamoyl diester of the dietary polyphenol curcumin offers improved protection against peroxynitrite-mediated nitrosative stress and damage of brain mitochondria in vitro: implications for Parkinson's disease.

Authors:  Rajeswara Babu Mythri; G Harish; Shiv Kumar Dubey; Krishna Misra; M M Srinivas Bharath
Journal:  Mol Cell Biochem       Date:  2010-10-23       Impact factor: 3.396

4.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

Review 5.  Mechanistic approaches to predicting oral drug absorption.

Authors:  Weili Huang; Sau Lawrence Lee; Lawrence X Yu
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

6.  Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.

Authors:  M D Pescovitz; J Rabkin; R M Merion; C V Paya; J Pirsch; R B Freeman; J O'Grady; C Robinson; Z To; K Wren; L Banken; W Buhles; F Brown
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.

Authors:  A Jayaprakash Patil; Ashish Sharma; M Cristina Kenney; Baruch D Kuppermann
Journal:  Clin Ophthalmol       Date:  2010-03-04

Review 8.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

Review 9.  Recent trends in targeted anticancer prodrug and conjugate design.

Authors:  Yashveer Singh; Matthew Palombo; Patrick J Sinko
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

10.  Evolution of an amino acid based prodrug approach: stay tuned.

Authors:  Ivan S Krylov; Boris A Kashemirov; John M Hilfinger; Charles E McKenna
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.